Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-specific shared antigenic peptides recognized by human T cells.

Pierre Van Der Bruggen1, Yi Zhang, Pascal Chaux

  • 1Ludwig Institute for Cancer Research and Cellular Genetics Unit, Université de Louvain, 74 avenue Hippocrate UCL 74.59, B-1200 Brussels, Belgium. pierre.vanderbruggen@bru.licr.org

Immunological Reviews
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunity.

bioRxiv : the preprint server for biology·2026
Same author

Clathrin-independent endocytosis and retrograde transport in cancer cells tune immune synapse organization and CD8 T cell response.

eLife·2026
Same author

Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF.

Science immunology·2026
Same author

Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype.

Frontiers in immunology·2025
Same author

Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2025
Same author

IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti-PD-1 Therapy in Tumor-Bearing Mice.

Cancer immunology research·2025

Researchers identified tumor-specific antigens using cancer-germline genes. New reverse immunology methods reveal more cancer-associated antigenic peptides for T cell therapies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Initial identification of tumor-specific shared antigens and cancer-germline genes was achieved via antitumor cytolytic T lymphocytes from cancer patients.
  • A limited number of HLA class I-restricted antigenic peptides were identified using a 'direct approach'.

Purpose of the Study:

  • To review recent 'reverse immunology' approaches for identifying novel antigenic peptides.
  • To discuss the processing and presentation of these antigenic peptides.

Main Methods:

  • Genetic approaches and screening of tumor cDNA expression libraries identified numerous cancer-germline genes.
  • Reverse immunology methods involve in vitro stimulation of naive T cells with dendritic cells loaded with cancer-germline proteins or viral gene sequences.

Related Experiment Videos

Main Results:

  • Numerous cancer-germline genes coding for tumor-specific shared antigens are known, though most encoded antigenic peptides remain unidentified.
  • Reverse immunology approaches have successfully identified many new antigenic peptides presented by both class I and class II molecules.

Conclusions:

  • Reverse immunology offers powerful strategies for discovering new antigenic peptides crucial for cancer immunotherapy.
  • Understanding the processing and presentation of these peptides is vital for developing effective cancer vaccines and T cell therapies.